Zydus Lifesciences Arm Secures Global Rights to Brazil’s Braile Biomedica’s TAVI System

Zydus Medtech, a subsidiary of Zydus Lifesciences, has signed a global licensing agreement with Brazil-based Braile Biomedica to commercialise its Transcatheter Aortic Valve Implantation (TAVI) system. The deal covers markets in India, Europe, and other selected regions.

As of 9:24 am on April 21, 2025, Zydus Lifesciences share price was trading at ₹831.75, a 0.024% up, down 17.38% over the past six months and 13.42% over the past year.

Rights and Responsibilities

Under the agreement, Zydus Medtech will hold exclusive rights to market Braile Biomedica’s balloon-expandable TAVI system in the mentioned geographies. Braile will continue manufacturing the device in Brazil, while Zydus will manage marketing and regulatory operations. In some cases, Zydus will also produce specific components of the system.

Market Context

The global market for TAVI devices is currently valued at over USD 6 billion. Demand has grown steadily due to the increasing preference for less invasive cardiac procedures. The partnership allows Zydus Medtech to enter the structural heart therapy space, where the company is actively building its interventional cardiology portfolio.

Plans

A clinical research programme for the TAVI device is expected to start next year. In addition to the current system, the agreement includes plans for a pipeline of new products to be launched over the next three years.

Overview

Zydus Lifesciences employs more than 27,000 people worldwide, including over 1,400 researchers. Braile Biomedica has nearly five decades of experience in cardiovascular device development and operates across Latin America.

The TAVI system is a medical device used in minimally invasive procedures to treat aortic stenosis. It is particularly used for elderly patients or those considered high-risk for open-heart surgery. The system uses a valve constructed from a single sheet of bovine pericardium, which differs from the standard three-leaflet structure. This design was initially developed as part of a doctoral thesis by cardiac surgeon Dr. Domingo Braile.

Read More: Why Did Lupin and Zydus Share Price Decline Sharply?

Conclusion

The licensing deal enables Zydus Medtech to expand its offerings in the cardiovascular space while supporting the global distribution of Braile’s TAVI technology.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.